Serum complement activation on heterologous platelets is associated with arterial thrombosis in patients with systemic lupus erythematosus and antiphospholipid antibodies
Restricted accessResearch articleFirst published online May, 2009
Serum complement activation on heterologous platelets is associated with arterial thrombosis in patients with systemic lupus erythematosus and antiphospholipid antibodies
Complement plays a major role in inflammation and thrombosis associated with systemic lupus erythematosus (SLE) and the antiphospholipid syndrome (APS). A cross-sectional retrospective analysis was performed to evaluate serum complement fixation on platelets and thrombotic incidence using banked sera and clinical data from patients with SLE (n = 91), SLE with antiphospholipid antibodies (aPL) or APS (n = 78) and primary aPL (n = 57) or APS (n = 96). In-situ complement fixation was measured as C1q and C4d deposition on heterologous platelets using an enzyme-linked immunosorbent assay approach. Platelet activation by patient serum in the fluid phase was assessed via serotonin release assay. Enhanced in-situ complement fixation was associated with the presence of IgG aPL and IgG anti-β2 glycoprotein 1 antibodies (P < 0.05) and increased platelet activation (P < 0.005). Moreover, enhanced complement fixation, especially C4d deposition on heterologous platelets, was positively associated with arterial thrombotic events in patients with SLE and aPL (P = 0.039). Sera from patients with aPL possess an enhanced capacity for in-situ complement fixation on platelets. This capacity may influence arterial thrombosis risk in patients with SLE.
1 Giannakopoulos B Passam F Rahgozar S Krillis SA . Current concepts on the pathogenesis of the antiphospholipid syndrome. Blood2007; 109: 422–430.
2.
2 Wilson WA Gharavi AE Koike T . International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum2000; 42: 1309–1311.
3.
3 Petri M . Epidemiology of the antiphospholipid antibody syndrome. J Autoimmun2000; 15: 145–151.
5 Simantov R LaSala JM Lo DK Gharavi AE Sammaritano LR Salmon JE . Activation of cultured vascular endothelial cells by antiphospholipid antibodies. J Clin Invest1995; 96: 2211–2219.
6.
6 Pierangeli SS Colden-Stanfield M Liu X Barker JH Anderson GL Harris EN . Antiphospholipid antibodies from antiphospholipid syndrome patients: activation of endothelial cells in vitro and in vivo. Circulation1999; 99: 1007–2002.
7.
7 DeJong A Ziboh V Robbins D . Antiphospholipid antibodies and platelets. Curr Rheumatol Rep2000; 2: 238–245.
8.
8 Piona A la Rosa L Tincani A . Placental thrombosis and fetal loss after passive transfer of mouse lupus monoclonal or human polyclonal anti-cardiolipin antibodies in pregnant naïve BALB/c mice. Scand J Immunol1995; 41: 427–432.
9.
9 Shi W Chong BH Chesterman CN . β2-glycoprotein 1 is a requirement for anticardiolipin antibodies binding to activated platelets: differences with lupus anticoagulants. Blood1993; 81: 1255–1262.
10.
10 Levine JS Branch W Rauch J . The antiphospholipid syndrome. N Engl J Med2002; 346: 752–763.
11.
11 Salmon JE Girardi G . The role of complement in antiphospholipid syndrome. Curr Dir Autoimmun2004; 7: 133–148.
12.
12 Pennings MT Derksen RH van Lummel M . Platelet adhesion to dimeric beta-glycoprotein 1 under conditions of flow is mediated by at least two receptors: glycoprotein Ib alpha and apolipoprotein E receptor 2’. J Thromb Haemost2007; 5: 369–377.
13.
13 Davis WD Brey RL . Antiphospholipid antibodies and complement activation in patients with cerebral ischemia. Clin Exp Immunol1992; 10: 445–460.
14.
14 Shinzato MM Bueno C Trindade Viana VS Borba EF Goncalves CR Bonfa E . Complement-fixing activity of anticardiolipin antibodies in patients with and without thrombosis. Lupus2005; 14: 953–958.
15.
15 Navratil JS Manzi S Kao AH . Platelet C4d is highly specific for systemic lupus erythematosus. Arthritis Rheum2006; 54: 670–674.
16.
16 Peerschke EIB Yin W Grigg SE Ghebrehiwet B . Blood platelets activate the classical pathway of human complement. J Thromb Haemost2006; 4: 2035–2042.
17.
17 Tan EM Cohen AS Fries JF . The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum1982; 25: 1271–1277.
18.
18 Alpert D Mandl LA Erkan D Yin W Peerschke EI Salmon JE . Anti- heparin platelet factor 4 antibodies in systemic lupus erythematosus are associated with IgM antiphospholipid antibodies and the antiphospholipid syndrome. Ann Rheum Dis2008; 67: 395–401.
19.
19 Merkel PA Chang Y Pierangeli SS Harris EN Polisson RP . Comparison between the standard anticardiolipin antibody test and a new phospholipid test in patients with connective tissue diseases. J Rheumatol1999; 26: 591–596.
20.
20 Pierangeli S Henderson V Pappalardo E . Evaluation of several ELISA tests used in the diagnosis of antiphospholipid syndrome in a large cohort of patient samples. Arthritis Rheum2006; 54(Suppl): S553.
21.
21 Harris EN Pierangeli S Birch D . Anticardiolipin wet workshop report. Fifth International Symposium on antiphospholipid antibodies. Am J Clin Pathol1994; 101: 616–624.
22.
22 Peerschke EI Zucker MB Grant RA Egan JJ Johnson MM . Correlation between fibrinogen binding to human platelets and platelet aggregability. Blood1980; 55: 841–847.
23.
23 Huber-Lang M Sarma SV Zetoune FS . Generation of C5a in the absence of C3: a new complement pathway. Nat Med2006; 12: 682–687.
24.
24 Peerschke EI . Induction of human platelet fibrinogen receptor by epinephrine in the absence of released ADP. Blood1982; 60: 71–77.
25.
25 Frank MM . Complement in the pathophysiology of human disease. N Engl J Med1987; 316: 1525–1530.
26.
26 Pickering MC Botto M Taylor PR Lachmann PJ Walport MJ . Systemic lupus erythematosus, complement deficiency, and apoptosis. Adv Immunol2000; 76: 227–324.
27.
27 Truedsson L Bengtsson AA Sturfelt G . Complement deficiencies and systemic lupus erythematosus. Autoimmunity2007; 40: 560–566.
28.
28 Tyrell DJ Kilfeather S Page CP . Therapeutic uses of heparin beyond its traditional role as an anticoagulant. Trends Pharmacol Sci1995; 16: 198–204.
29.
29 Mollnes TE Garred P Bergseth G . Effect of time, temperature and anticoagulants on in vitro complement activation: consequences for collection and preservation of samples to be examined for complement activation. Clin Exp Immunol1988; 73: 484–488.
30.
30 Sims PJ Rollins SA Wiedmer T . Regulatory control of complement on blood platelets. Modulation of platelet procoagulant reponses by a membrane inhibitor of the C5b-9 complex. J Biol Chem1989; 264: 19228–19235.
31.
31 Markiewski MM Lambris JD . The role of complement in inflammatory diseases from behind the scenes into the spotlight. Am J Pathol2007; 171: 715–727.
33 Kornberg A Blank M Kaufman S Shoenfeld Y . Induction of tissue factor-like activity in monocytes by anti-cardiolipin antibodies. J Immunol1994; 153: 1328–1332.
34.
34 Meroni PL Borghi MO Raschi E . Inflammatory response and the endothelium. Thromb Res2004; 114: 329–334.
35.
35 Jagels MA Daffern PJ Hugli TE . C3a and C5a enhance granulocyte adhesion to endothelial and epithelial cell monolayers: epithelial and endothelial priming is required for C3a-induced eosinophil adhesion. Immunopharmacology2000; 46: 209–222.
36.
36 Ikeda K Nagasawa K Horiuchi T Tsuru T Nishizaka H Niho Y . C5a induces tissue factor activity on endothelial cells. Thromb Haemost1997; 77: 294–398.
37.
37 Oksjoki R Laine P Helske S . Receptors for the anaphylatoxins C3a and C5a are expressed in human atherosclerotic coronary plaques. Atherosclerosis2007; 195: 90–99.
38.
38 Petri M . Classification and epidemiology of the antiphospholipid syndrome. In: RA Asherson R Cervera JC Piette Y Shoenfeld , (eds), The antiphospholipid syndrome II: autoimmune thrombosis.Amsterdam: Elsevier; 2002. p. 11–20.
39.
39 Rand JH . Molecular pathogenesis of the antiphospholipid syndrome. Circ Res2002; 90: 29–37.
40.
40 Mok CC . Accelerated atherosoclerosis, arterial thromboembolism, and preventive strategies in systemic lupus erythematosus. Scand J Rheumatol2006; 35: 85–95.
41.
41 Haque S Bruce IN . Therapy insight: systemic lupus erythematosus as a risk factor for cardiovascular disease. Nat Clin Pract Cardiovasc Med2005; 2: 423–430.
42.
42 Erkan D . Lupus and Thrombosis. J Rheumatol2006; 33: 1715–1717.
